- This event has passed.
Event Navigation
When (do?) “Guidelines” Diverge from “Best Practices”
Mark Schumacher, MD, PhD
Proper Charting & Documentation &
When Should You Taper (or Not Taper)?
Samir Sheth, MD
Pharmacology & Use of Buprenorphine, Naloxone & Low Dose Naltrexone (LDN)
Avinash Ramchandani, MD, MBA
Additional Reading
- Darnall, B. D., Juurlink, D., Kerns, R. D., Mackey, S., Van Dorsten, B., Humphreys, K., … & Hoffman, D. E. (2018). International stakeholder community of pain experts and leaders call for an urgent action on forced opioid tapering. Pain Medicine, 20(3), 429-433.
- Von Korff, M., Saunders, K., Ray, G. T., Boudreau, D., Campbell, C., Merrill, J., … & Weisner, C. (2008). Defacto long-term opioid therapy for non-cancer pain. The Clinical journal of pain, 24(6), 521.
- Campbell, C. I., Weisner, C., LeResche, L., Ray, G. T., Saunders, K., Sullivan, M. D., … & Satre, D. D. (2010). Age and gender trends in long-term opioid analgesic use for noncancer pain. American journal of public health, 100(12), 2541-2547.
- Kroenke, K., Alford, D. P., Argoff, C., Canlas, B., Covington, E., Frank, J. W., … & Kravitz, R. L. (2019). Challenges with implementing the centers for disease control and prevention opioid guideline: a consensus panel report. Pain Medicine, 20(4), 724-735.
- Corder, G., Tawfik, V. L., Wang, D., Sypek, E. I., Low, S. A., Dickinson, J. R., … & Scherrer, G. (2017). Loss of μ opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia. Nature medicine, 23(2), 164.
- Davis, M. P. (2012). Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol, 10(6), 209-219.